gdc

Web Exclusives

A Healthy Diet May Reduce the Risk of Cancer
Nutrition & Cancer
Web Exclusives – February 8, 2022
Based on current and evolving scientific evidence, the cancer prevention guidelines have been shifting from a nutrient-centric approach to a more holistic approach of diet that is characterized as dietary patterns.
Close the Gap in Cancer Care: We Are All Interconnected in Wellness
World Cancer Day
Web Exclusives – February 4, 2022
Cancer affects all races, ethnicities, sexual orientations, genders, and nationalities.
Can You Get Pregnant If You Have Cervical Cancer?
Cervical Cancer
Web Exclusives – January 13, 2022
Cervical cancer during pregnancy can be successfully managed with a multidisciplinary treatment team and an individualized treatment strategy that optimizes maternal treatment while considering fetal safety.
FDA Approved Fyarro for Malignant Perivascular Epithelioid-Cell Tumor
FDA Approvals, News & Updates
Web Exclusives – December 21, 2021

On November 22, 2021, the FDA approved Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound); from Aadi Bioscience) for adults with locally advanced, unresectable or metastatic malignant perivascular epithelioid-cell tumor (PEComa), a rare type of mesenchymal tumors that can occur in any part of the body.

Jemperli a New Immunotherapy Approved for All Patients with dMMR Solid Tumors
FDA Approvals, News & UpdatesImmunotherapy
Web Exclusives – December 14, 2021
On August 17, 2021, the FDA accelerated the approval of Jemperli (dostarlimab-gxly; from GlaxoSmithKline) injection, an immunotherapy and a PD-1 inhibitor, for the treatment of all adults with recurrent (coming back) or advanced mismatch repair-deficient (dMMR) solid tumors, including lung cancer, that progressed during or after systemic therapy and for whom there are no satisfactory alternative treatment options.
Reasons for Optimism for Patients with Cancer Facing Another Winter with COVID-19
COVID-19 & Cancer
Web Exclusives – December 1, 2021
Although we are entering another winter with the ongoing prevalence of the coronavirus, we have come a long way since the initial outbreak. Here are some reasons for patients to be optimistic for the season.
Combining Targeted Therapies in CLL
CLL Monthly MinutesLeukemia
Web Exclusives – November 17, 2021
The combination of acalabrutinib, venetoclax, and obinutuzumab has been shown to be an active regimen in previously untreated patients with CLL.
A Comprehensive Analysis of COVID-19 in Patients with CLL
CLL Monthly MinutesLeukemia
Web Exclusives – November 17, 2021
During the first 13 months of the pandemic, COVID-19 continued to result in high hospitalization rates among patients with CLL.
Infections in Patients with CLL Receiving Ibrutinib
CLL Monthly MinutesLeukemia
Web Exclusives – November 17, 2021
Identifying the risk factors for infection may allow preventive measures to be taken to protect patients.
Measuring Treatment Adherence to Oral Therapies in Patients with CLL
CLL Monthly MinutesLeukemia
Web Exclusives – November 17, 2021
Oral targeted therapies have revolutionized treatment for patients with CLL but ensuring that they are taken as prescribed is crucial to achieving optimal outcomes.
Page 3 of 24
Results 21 - 30 of 236

Subscribe to CONQUER: the journey informed

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests